227 related articles for article (PubMed ID: 21874414)
1. Topoisomerase I expression in tumors as a biological marker for CPT-11 chemosensitivity in patients with colorectal cancer.
Ikeguchi M; Arai Y; Maeta Y; Ashida K; Katano K; Wakatsuki T
Surg Today; 2011 Sep; 41(9):1196-9. PubMed ID: 21874414
[TBL] [Abstract][Full Text] [Related]
2. Quantitative analysis of DNA topoisomerase I activity in human and rat glioma: characterization and mechanism of resistance to antitopoisomerase chemical, camptothecin-11.
Matsumoto Y; Fujiwara T; Honjo Y; Sasaoka N; Tsuchida T; Nagao S
J Surg Oncol; 1993 Jun; 53(2):97-103. PubMed ID: 8388965
[TBL] [Abstract][Full Text] [Related]
3. CPT-11 in the treatment of colorectal cancer: clinical efficacy and safety profile.
Rougier P; Bugat R
Semin Oncol; 1996 Feb; 23(1 Suppl 3):34-41. PubMed ID: 8633252
[TBL] [Abstract][Full Text] [Related]
4. The role of irinotecan in colorectal cancer.
Saltz LB
Curr Oncol Rep; 1999; 1(2):155-60. PubMed ID: 11122813
[TBL] [Abstract][Full Text] [Related]
5. CPT-11 (irinotecan) in the treatment of colorectal cancer.
Armand JP; Ducreux M; Mahjoubi M; Abigerges D; Bugat R; Chabot G; Herait P; de Forni M; Rougier P
Eur J Cancer; 1995; 31A(7-8):1283-7. PubMed ID: 7577037
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic targeting of CPT-11 induced diarrhea: a case for prophylaxis.
Swami U; Goel S; Mani S
Curr Drug Targets; 2013 Jun; 14(7):777-97. PubMed ID: 23597015
[TBL] [Abstract][Full Text] [Related]
7. 7-Ethyl-10-[4-(1-piperidino)-1-piperidino] carbonyloxy camptothecin: mechanism of resistance and clinical trials.
Saijo N; Nishio K; Kubota N; Kanzawa F; Shinkai T; Karato A; Sasaki Y; Eguchi K; Tamura T; Ohe Y
Cancer Chemother Pharmacol; 1994; 34 Suppl():S112-7. PubMed ID: 8070019
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and toxicity of irinotecan in patients with colorectal cancer.
Rothenberg ML
Semin Oncol; 1998 Oct; 25(5 Suppl 11):39-46. PubMed ID: 9786315
[TBL] [Abstract][Full Text] [Related]
9. Topoisomerase I but not thymidylate synthase is associated with improved outcome in patients with resected colorectal cancer treated with irinotecan containing adjuvant chemotherapy.
Kostopoulos I; Karavasilis V; Karina M; Bobos M; Xiros N; Pentheroudakis G; Kafiri G; Papakostas P; Vrettou E; Fountzilas G
BMC Cancer; 2009 Sep; 9():339. PubMed ID: 19775480
[TBL] [Abstract][Full Text] [Related]
10. [Clinical significant of semiquantificating DNA topoisomerase- I mRNA in colorectal cancer].
Ishida H; Shirakawa K; Ohsawa T; Hayashi Y; Okada N; Nakada H; Yokoyama M
Gan To Kagaku Ryoho; 2005 Sep; 32(9):1295-9. PubMed ID: 16184927
[TBL] [Abstract][Full Text] [Related]
11. [Therapeutic approach for colorectal cancer with topoisomerase as a molecular target].
Tsunoda T
Nihon Rinsho; 2003 Sep; 61 Suppl 7():472-5. PubMed ID: 14574938
[No Abstract] [Full Text] [Related]
12. CES2, ABCG2, TS and Topo-I primary and synchronous metastasis expression and clinical outcome in metastatic colorectal cancer patients treated with first-line FOLFIRI regimen.
Silvestris N; Simone G; Partipilo G; Scarpi E; Lorusso V; Brunetti AE; Maiello E; Paradiso A; Mangia A
Int J Mol Sci; 2014 Sep; 15(9):15767-77. PubMed ID: 25198900
[TBL] [Abstract][Full Text] [Related]
13. Treatment of advanced or recurrent colorectal cancer with irinotecan in Japan and elsewhere.
Sato T; Hatate K; Ikeda A; Yamanashi T; Ozawa H; Onosato W; Nakamura T; Ihara A; Watanabe M
Expert Opin Pharmacother; 2008 May; 9(7):1223-8. PubMed ID: 18422478
[TBL] [Abstract][Full Text] [Related]
14. The current status of camptothecin analogues as antitumor agents.
Slichenmyer WJ; Rowinsky EK; Donehower RC; Kaufmann SH
J Natl Cancer Inst; 1993 Feb; 85(4):271-91. PubMed ID: 8381186
[TBL] [Abstract][Full Text] [Related]
15. Cellular parameters predictive of the clinical response of colorectal cancers to irinotecan. A preliminary study.
Pavillard V; Charasson V; Laroche-Clary A; Soubeyran I; Robert J
Anticancer Res; 2004; 24(2B):579-85. PubMed ID: 15160997
[TBL] [Abstract][Full Text] [Related]
16. Topoisomerase I-DNA covalent complexes in human colorectal cancer xenografts with different p53 and microsatellite instability status: relation with their sensitivity to CTP-11.
Lansiaux A; Bras-Goncalves RA; Rosty C; Laurent-Puig P; Poupon MF; Bailly C
Anticancer Res; 2001; 21(1A):471-6. PubMed ID: 11299781
[TBL] [Abstract][Full Text] [Related]
17. Synergistic interaction between the EGFR tyrosine kinase inhibitor gefitinib ("Iressa") and the DNA topoisomerase I inhibitor CPT-11 (irinotecan) in human colorectal cancer cells.
Koizumi F; Kanzawa F; Ueda Y; Koh Y; Tsukiyama S; Taguchi F; Tamura T; Saijo N; Nishio K
Int J Cancer; 2004 Jan; 108(3):464-72. PubMed ID: 14648715
[TBL] [Abstract][Full Text] [Related]
18. [Prognostic value of thymidylate synthase, topoisomerase-1 and Ki-67 in advanced colorectal cancer patients on irinotecan and fluorouracil treatment].
Xu JM; Zhu BD; Mangia A; Simone G; Montemurro S; Giuliani F; Maiello E; Colucci G; Paradiso A
Zhonghua Zhong Liu Za Zhi; 2005 May; 27(5):312-5. PubMed ID: 15996331
[TBL] [Abstract][Full Text] [Related]
19. CPT-11 (irinotecan) in the treatment of colorectal cancer: a new mechanism of action for additional activity.
Bleiberg H
Tumori; 1997; 83(1 Suppl):S85-6. PubMed ID: 9154078
[No Abstract] [Full Text] [Related]
20. Delta-24 increases the expression and activity of topoisomerase I and enhances the antiglioma effect of irinotecan.
Gomez-Manzano C; Alonso MM; Yung WK; McCormick F; Curiel DT; Lang FF; Jiang H; Bekele BN; Zhou X; Alemany R; Fueyo J
Clin Cancer Res; 2006 Jan; 12(2):556-62. PubMed ID: 16428500
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
